HC Wainwright Expects Reduced Earnings for Legend Biotech

Legend Biotech Co. (NASDAQ:LEGN) – Research analysts at HC Wainwright lowered their Q4 2025 earnings per share (EPS) estimates for shares of Legend Biotech in a note issued to investors on Wednesday, March 12th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of $0.11 for the quarter, down from their prior forecast of $0.12. HC Wainwright has a “Buy” rating and a $75.00 price objective on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is ($1.31) per share.

A number of other research analysts also recently commented on the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $86.00 target price on shares of Legend Biotech in a report on Monday, December 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $83.00 target price on shares of Legend Biotech in a report on Monday, December 9th. Guggenheim reaffirmed a “neutral” rating on shares of Legend Biotech in a report on Wednesday. Finally, Piper Sandler reissued an “overweight” rating and issued a $78.00 price target on shares of Legend Biotech in a report on Monday, December 30th. One equities research analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $79.09.

Legend Biotech Trading Down 2.2 %

NASDAQ:LEGN opened at $37.20 on Friday. The company has a quick ratio of 4.90, a current ratio of 4.98 and a debt-to-equity ratio of 0.27. The business’s 50 day moving average is $35.68 and its two-hundred day moving average is $40.97. Legend Biotech has a 52 week low of $30.17 and a 52 week high of $69.17. The company has a market cap of $6.79 billion, a PE ratio of -39.16 and a beta of 0.19.

Legend Biotech (NASDAQ:LEGN) last released its earnings results on Tuesday, March 11th. The company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.46. Legend Biotech had a negative return on equity of 29.69% and a negative net margin of 66.92%. The company had revenue of $186.50 million for the quarter, compared to the consensus estimate of $179.00 million. During the same quarter last year, the business posted ($0.40) EPS. Legend Biotech’s quarterly revenue was up 134.6% compared to the same quarter last year.

Institutional Trading of Legend Biotech

Several hedge funds have recently added to or reduced their stakes in the business. FMR LLC raised its stake in Legend Biotech by 4.0% during the 3rd quarter. FMR LLC now owns 18,330,219 shares of the company’s stock valued at $893,232,000 after acquiring an additional 708,620 shares in the last quarter. Westfield Capital Management Co. LP raised its stake in Legend Biotech by 5.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 5,038,505 shares of the company’s stock valued at $245,526,000 after acquiring an additional 266,296 shares in the last quarter. Suvretta Capital Management LLC bought a new stake in Legend Biotech during the 4th quarter valued at $113,767,000. Invesco Ltd. raised its stake in Legend Biotech by 44.7% during the 4th quarter. Invesco Ltd. now owns 3,309,971 shares of the company’s stock valued at $107,706,000 after acquiring an additional 1,022,365 shares in the last quarter. Finally, Braidwell LP raised its stake in Legend Biotech by 93.2% during the 4th quarter. Braidwell LP now owns 2,977,951 shares of the company’s stock valued at $96,903,000 after acquiring an additional 1,436,400 shares in the last quarter. Institutional investors own 70.89% of the company’s stock.

About Legend Biotech

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).